GIFT City, India · New Jersey, USA

Advancing Global
Healthcare Through
Scientific Innovation

A research-driven pharmaceutical and bioscience institution headquartered at GIFT City, India — structured for global regulated markets with WHO-GMP alignment, 10+ therapeutic platforms, and the Truvedika Ayurvedic wellness division.

10+
Therapeutic Platforms
6
R&D Disciplines
2
Global Territories
Scroll to explore
WHO-GMP Regulatory Aligned
GIFT City India Headquarters
New Jersey USA Operations
Truvedika Ayurvedic Division
CTD/eCTD Dossier Ready
USFDA · EMA · CDSCO Compliant
$1.6T+ Global Pharma Market
8–10% India Pharma CAGR
WHO-GMP Regulatory Aligned
GIFT City India Headquarters
New Jersey USA Operations
Truvedika Ayurvedic Division
CTD/eCTD Dossier Ready
USFDA · EMA · CDSCO Compliant
$1.6T+ Global Pharma Market
8–10% India Pharma CAGR
Company Snapshot

India-Anchored.
Globally Structured.

10+
Therapeutic Categories
6
R&D Platforms
2
Global Territories
4
Active SKUs

Institution-Built

Long-horizon governance with regulatory infrastructure designed for multi-decade healthcare value creation across global markets.

About SCIBEX

Built to Last.
Built to Lead.

SCIBEX BIOSCIENCES Pvt. Ltd. is a research-driven pharmaceutical and bioscience company headquartered at GIFT City, Gandhinagar, Gujarat — India's first Smart City and International Financial Services Centre.

We operate at the convergence of pharmaceutical science, formulation innovation, and integrative bioscience, structured to serve global healthcare markets with precision, scientific rigour, and institutional integrity.

Mission

To advance accessible, evidence-based pharmaceutical solutions that improve long-term population health outcomes globally.

Vision

To be recognized as a trusted global bioscience institution known for scientific leadership, regulatory excellence, and long-term patient value.

At a Glance

Company
Profile

Founded on the principle that world-class pharmaceutical research can be anchored in India and scaled globally.

Legal NameSCIBEX BIOSCIENCES Pvt. Ltd.
IncorporatedGIFT City, Gandhinagar, Gujarat, India
US EntitySCIBEX BIOSCIENCES Inc. — New Jersey, USA
Chairman & MDHarsh Shah
Chief Technology OfficerPurvesh Shah
Chief Financial OfficerShubham Sharma
Co-FounderHemant Shah
Ayurvedic DivisionTruvedika — www.truvedika.com ↗
Therapeutic Focus10 Clinical Categories
Regulatory FrameworkCDSCO • WHO-GMP • USFDA • EMA • ICH • CTD
Expansion RoadmapIndia → USA → SE Asia → Europe/MENA
Websitewww.scibexbiosciences.com ↗
Research & Innovation

Six Integrated
R&D Platforms

End-to-end pharmaceutical value chain — from scientific concept to regulated global market

01

Formulation Development

Proprietary formulation science for oral solid dosage forms, modified-release systems, and targeted drug delivery architectures.

TabletsCapsulesMR SystemsPellets
02
🔬

Analytical Sciences

Rigorous quality control through HPLC, dissolution testing, stability protocols, and validated analytical methods ensuring full regulatory compliance.

HPLCDissolutionStability
03
🧬

Bioscience Integration

Interdisciplinary science combining molecular biology, PK/PD modeling, and clinical data to build evidence-supported therapeutic portfolios.

PK/PDBioavailabilityMolecular
04
📋

Regulatory Sciences

Dedicated regulatory affairs aligned with CDSCO, USFDA, EMA, and WHO-GMP. Complete CTD/eCTD dossier preparation and pharmacovigilance.

USFDAEMACTD/eCTDICH
05
🌿

Preventive Health Technologies

Nutraceutical science, immunomodulatory compounds, and evidence-based preventive formulations targeting chronic lifestyle and metabolic disorders.

NutraceuticalsAdaptogensMetabolic
06

Product Lifecycle Management

Structured PLM from IND through NDA to post-marketing surveillance, ensuring regulatory compliance and commercial maximization at every stage.

INDNDAANDAPV
Therapeutic Portfolio

10 Clinical Focus Areas

Spanning chronic disease, lifestyle disorders, and evidence-based preventive healthcare — targeting the world's most significant unmet clinical needs

Very High 01
Cardiovascular
Hypertension, dyslipidemia, heart failure, CAD
Very High 02
Diabetes & Metabolic
T2DM, insulin resistance, obesity, MetS
High 03
Gastrointestinal
IBS, GERD, peptic ulcer, IBD, hepatic support
High 04
Respiratory
Asthma, COPD, bronchitis, pulmonary conditions
High 05
Pain & Inflammation
Musculoskeletal, neuropathic, acute pain
Growing 06
Mental Wellness
Anxiety, depression, sleep, ADHD, cognition
High 07
Immunity & Infection
Immunomodulation, autoimmune, prophylaxis
High 08
Women's Health
PCOS, endometriosis, hormonal, maternal
Medium 09
Urology
BPH, UTI, renal support, chronic conditions
Medium 10
Dermatology
Acne, eczema, psoriasis, hyperpigmentation
Quality & Regulatory

Regulatory Excellence

Full compliance with international pharmaceutical regulations — audit-ready at every stage of development and manufacturing.

CDSCO
WHO-GMP
USFDA
EMA
ICH
CTD/eCTD
Schedule M
01

GMP-Aligned Manufacturing

Facilities designed in strict alignment with WHO-GMP and Schedule M frameworks. Full audit readiness for national and international inspections.

02

Pharmacovigilance Systems

Comprehensive post-market safety surveillance including adverse event monitoring, signal detection, ICSR reporting per ICH E2 guidelines.

03

Regulatory Dossier Management

Complete CTD/eCTD documentation for CDSCO, USFDA, and EMA submissions with structured technical writing and archival systems.

04

Stability & Analytical Testing

ICH Q1A/Q1B accelerated and real-time stability studies, validated HPLC methodologies ensuring pharmaceutical quality across shelf life.

05

Change Control & CAPA

Formal deviation management, root-cause investigation, CAPA workflows, and version-controlled SOP documentation maintaining continuous quality integrity.

06

Supplier Qualification & Audit

Systematic qualification of API, excipient, and packaging material suppliers through vendor audits, CoA review, and approved supplier listing.

Global Operations

India-Rooted.
Globally Expanding.

Dual-territory operations platform connecting India's pharmaceutical excellence to world markets.

🇮🇳
Active — Phase 1

India Headquarters

GIFT City, Gujarat

SCIBEX BIOSCIENCES Pvt. Ltd., GIFT City (Gujarat International Finance Tec-City), Gandhinagar, Gujarat 382 355. India's premier institutional hub providing regulatory proximity, world-class infrastructure, and direct access to pharmaceutical sector leadership and capital markets.

Phone: +91 9974062755 business@scibexbiosciences.com www.scibexbiosciences.com
🇺🇸
In Progress — Phase 2

USA Operations

New Jersey, USA

SCIBEX BIOSCIENCES Inc., New Jersey — US East Coast Pharmaceutical Corridor. Strategic gateway into the world's largest pharmaceutical market. Positioned to support Medical Affairs, USFDA regulatory submissions, licensing and partnership development.

Phone: +1 551 256 0660 Medical Affairs Regulatory Filings & Partnership Development
1
Active
India
GIFT City, Gujarat
2
In Progress
USA
New Jersey, NJ
3
Pipeline 2026
SE Asia
Strategic Licensing
4
Horizon 2030
Europe / MENA
Licensing & Partnerships
Development Pipeline

8-Stage Development Pathway

1
Formulation Concept
4–6 mo
2
Pre-Formulation R&D
4–6 mo
3
Formulation Dev.
4–6 mo
4
Analytical Methods
4–6 mo
5
Stability Studies
4–6 mo
6
Dossier Prep.
4–6 mo
7
Regulatory Approval
6–12 mo
8
Commercial & PV
Ongoing
Therapeutic Priority Matrix
Therapeutic Area Priority Status Target Markets Timeline
CardiovascularVery HighActive DevelopmentIndia, USA, GCC18–24 Months
Diabetes & MetabolicVery HighActive DevelopmentIndia, USA, SE Asia18–24 Months
GastrointestinalHighFormulation StageIndia, GCC24–30 Months
RespiratoryHighPre-FormulationIndia, USA24–36 Months
Women's HealthHighActive DevelopmentIndia, MENA18–24 Months
Mental WellnessGrowingPipelineUSA, India30–42 Months
Market Opportunity

The Global Healthcare
Opportunity

India-based pharmaceutical companies uniquely positioned to capture global generics, specialty, and integrative wellness market growth.

$1.6T+
Global Pharma Market 2025
$57B+
India Pharma Market 2025
$13B+
Global Ayurvedic Wellness
8–10%
India Pharma CAGR Forecast
Why SCIBEX Biosciences
Science-first institution — WHO-GMP aligned, audit-ready manufacturing across all divisions
Dual jurisdiction: India GIFT City HQ + New Jersey USA operations fully established
10+ therapeutic areas with active formulation pipeline targeting highest-demand categories
Truvedika captures premium global Ayurvedic wellness demand in a $13B+ market
CTD/eCTD ready for USFDA, EMA, and CDSCO regulatory filings — submission-grade dossiers
Long-horizon governance model purpose-built for institutional capital and multi-decade value
GIFT City base — India's premier international financial services hub with global capital access
Experienced leadership across pharmaceutical science, technology, finance, and Ayurvedic medicine
Ayurvedic Wellness Division
TRUVEDIKA
Natural Ayura Company

A division of SCIBEX BIOSCIENCES Pvt. Ltd. — derived from Sanskrit, representing Truth (Satya), Knowledge (Vidya), and Holistic Healing. Every product is grounded in classical Ayurvedic texts — Charaka Samhita, Sushruta Samhita, Ashtanga Hridayam — validated through modern analytical methodology and GMP manufacturing standards.

Visit Truvedika Website
🏆
Best Young Startup Entrepreneur
🌟
Excellence in Ayurvedic Innovation
🌍
Emerging Global Healthcare Brand
01

Science-Backed Formulations

Rooted in classical Ayurvedic texts validated through modern analytical and clinical methodologies. Every ingredient authenticity verified and quality tested.

02

GMP Quality Manufacturing

Manufactured under GMP-compliant conditions using sustainably sourced, authentically identified botanical raw materials with full batch traceability.

03

Holistic Wellness Philosophy

Ayurveda's tridosha principle — addressing the root cause of imbalance. Whole-person wellness for modern, high-performance lifestyles.

04

Sustainability & Authenticity

Responsibly sourced herbs with full supply chain traceability, protecting India's biodiversity and supporting local farming communities.

Truvedika Products

Nature's Wisdom, Scientifically Proven

🌡
FEBRIVA
Ayurvedic Fever Recovery Syrup · 200ml
  • Thermal balance & recovery intelligence
  • Immunomodulatory botanical herbs
  • Post-fever strength restoration
  • Family suitable — all age groups
🫘
TRUPRA
Kidney & Urinary Care Formula · 200ml
  • Renal support & filtration function
  • Urinary tract health & integrity
  • Classical lithontriptic herbs
  • Safe for long-term use
🫀
Coming Soon
HEPRA
Liver Health & Detox Support · 200ml
  • Advanced hepatoprotection formula
  • Liver detoxification pathways
  • Oxidative stress reduction
  • Enzyme profile normalization
🫁
RESPIRA DNA
Respiratory & Immunity Support · 200ml
  • Bronchial health support formula
  • Immunomodulatory compound matrix
  • Anti-inflammatory respiratory action
  • Mint-infused for bioavailability

"Where Ayurvedic Wisdom Meets Modern Science"

Explore the complete Truvedika range

Visit www.truvedika.com ↗
Financial Overview

Financial Performance
& Growth Trajectory

The following financial figures are illustrative projections based on comparable pharma startup benchmarks. Verified audited financials will be provided to qualified institutional investors under NDA.
₹8.5 Cr
FY2025 Est. Revenue (India)
₹1.2 Cr
EBITDA FY2025 Est.
14%
EBITDA Margin
₹45 Cr
Revenue Target FY2027
Unit Economics & Key Metrics
Average Selling Price (Syrup 100ml)₹110–₹160
Gross Margin Target (Institutional)58–65%
Gross Margin (Retail / D2C)72–78%
Revenue per SKU per Year (Maturity)₹4 Cr – ₹6 Cr
Active SKUs (2025)4 (FEBRIVA, TRUPRA, HEPRA, RESPIRA)
Institutional Sales Cycle4–8 Weeks
Primary Revenue ChannelsTrade, Institutional, D2C, Export
Export Revenue Target (FY2028)30% of Total Revenue
R&D Investment (Annual)12–18% of Revenue
Trade & Pharmacy Channel45% of Revenue
Institutional & Tender20% of Revenue
D2C & E-Commerce20% of Revenue
Leadership Team

Group Leadership

Experienced executives across pharmaceutical science, technology, finance, and Ayurvedic medicine.

HS
Harsh Shah
Chairman & Managing Director
SCIBEX BIOSCIENCES + Truvedika (Chairman)

Founder and institutional leader. Brings deep expertise in pharmaceutical sciences, strategic governance, and long-term business development across India and global healthcare markets. Architect of SCIBEX's institutional vision.

PS
Purvesh Shah
Chief Technology Officer
SCIBEX BIOSCIENCES Pvt. Ltd.

Leads technology infrastructure, digital transformation, and scientific systems. Responsible for all R&D technology platforms, enterprise architecture, and innovation strategy across pharmaceutical and digital domains.

SS
Shubham Sharma
Chief Financial Officer
SCIBEX BIOSCIENCES + Truvedika

Oversees financial strategy, investor relations, corporate finance, and capital allocation across pharmaceutical and Ayurvedic divisions. Leads institutional fundraising, M&A evaluation, and financial governance frameworks.

HMS
Hemant Shah
Co-Founder & MD, Truvedika
SCIBEX BIOSCIENCES Co-Founder

Co-founder of SCIBEX and Managing Director of Truvedika. Deep expertise in Ayurvedic science, traditional medicine systems, and wellness brand development. Leads all Truvedika product and commercial strategy.

AS
Mrs. Asha Shah
Co-Founder & Director
Truvedika Natural Ayura Company

Co-founder and Director of Truvedika with deep passion for authentic Ayurvedic wellness and traditional knowledge systems. Oversees product quality philosophy and brand authenticity across all Truvedika formulations.

KS
Dr. Krisha Shah
Chief Ayurvedic Medical Officer
Truvedika (CAMO)

Responsible for all clinical formulation decisions, classical text-based product development, and therapeutic protocol design. Ensures authenticity, safety, and clinical relevance of all Truvedika formulations.

ESG & Governance

Institutional-Grade
Governance Framework

Structured for institutional transparency, long-term value creation, and sustainable growth. Built not for the quarter — but for the decade.

🏛

Board Governance

Independent oversight framework with audit, compliance, and scientific advisory committees ensuring accountability across all SCIBEX group entities.

📈

Growth Strategy

Disciplined organic R&D expansion, strategic licensing, branded partnerships, and phased market entry — India → USA → Global corridors.

🔍

Regulatory Transparency

Full disclosure framework for GMP, PV reporting, and regulatory status. Audit-ready documentation accessible to qualified institutional investors.

💡

Intellectual Property

Formulation patents, proprietary process development, and technology licensing as core IP value creation and competitive moat for SCIBEX.

Long-Term Value

Compounding value through diversified therapeutic portfolio, regulated market access, and science-led differentiation over a multi-decade institution-building horizon.

🌱

ESG Commitment

Responsible manufacturing, equitable access to medicines, biodiversity protection through Truvedika, and transparent governance across all group operations.

Get In Touch
"We exist to advance the health of people everywhere — through rigorous pharmaceutical science and the timeless wisdom of Ayurveda — one product, one patient, one generation at a time."
— SCIBEX BIOSCIENCES & Truvedika | GIFT City, Gujarat
business@scibexbiosciences.com
🇮🇳 India — Headquarters

SCIBEX BIOSCIENCES Pvt. Ltd.
GIFT City (Gujarat International Finance Tec-City)
Gandhinagar, Gujarat 382 355, India

+91 9974062755
business@scibexbiosciences.com
www.scibexbiosciences.com

🇺🇸 USA — Operations

SCIBEX BIOSCIENCES Inc.
New Jersey, United States of America
(US East Coast Pharmaceutical Corridor)

+1 551 256 0660
Medical Affairs · Regulatory Filings · Partnership Development

🌿 Truvedika — Ayurvedic Division

Under SCIBEX BIOSCIENCES Pvt. Ltd.
Products: FEBRIVA · TRUPRA · HEPRA · RESPIRA DNA

www.truvedika.com ↗